


Figure 1: ONWARD study design





Figure 2: Qualifying relapse rate (annualized, adjusted) in patients with SPMS treated with cladribine tablets 3.5 mg/kg + IFN-β or placebo + IFN-β in ONWARD

CI, confidence interval; IFN-β, interferon-β. SPMS, secondary progressive multiple sclerosis


Figure 3. Qualifying relapse rate (annualized, adjusted) in patients with RRMS treated with cladribine tablets 3.5 mg/kg + IFN-β or placebo + IFN-β in ONWARD
Qualifying relapse rate
0.8
0.4
0.4
0.3
0.2
0.1
0.0
0.31
0.15
Relative risk ratio (95% CI), 0.50 (0.30-0.84)
Risk reduction 50%
Placebo + IFN-β (N=48)
Cladribine 3.5 mg/kg + IFN-β (N=123)
CI, confidence interval; IFN-β, interferon-β. RRMS, relapsing-remitting multiple sclerosis




Figure 4 9-HPT=9-Hole Peg Test, EDSS= Expanded Disability Status Scale, MRI=magnetic resonance imaging; T25FW=Timed 25-Foot Walk, TP=treatment period.